What are the potential complications of a port-a-cath?

About This Drug. Eculizumab-xxxx (Soliris, Bkemv) is used to treat some blood disorders and nerve disorders. It is given in the vein (IV). View the fact sheet ... May 28, 2024 ... The US Food and Drug Administration approved Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab) to treat certain rare ... Jun 21, 2024 ... Soliris (eculizumab) is a monoclonal antibody that's approved for patients with atypical hemolytic uremic syndrome (aHUS). It specifically works ... This medication helps to block the decrease in red blood cells and can improve the symptoms of anemia (such as tiredness, shortness of breath) and decrease the ... Jan 7, 2022 ... Soliris® (eculizumab) is the first medication to be approved by the Australian Therapeutic Goods Administration (TGA) for the treatment of an MS ... Mar 7, 2025 ... Soliris, whose active substance is eculizumab, is a first‐in‐class biologic therapy designed to inhibit a key protein in the complement cascade— ... Oct 3, 2024 ... - Soliris is a complement inhibitor indicated for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis; atypical ... This article contains billing and coding guidelines that complement the Local Coverage Determination (LCD) Drugs and Biologicals, Coverage of, for Label and ... Mar 10, 2025 ... FDA Approves Expanded Use of Eculizumab (Soliris) for Pediatric Myasthenia Gravis, Bringing New Treatment Options for Children ... This landmark ... Apr 7, 2025 ... ... Soliris® (eculizumab), making it one of the greatest cost-saving biosimilars to Soliris ® in the U.S. Teva and Samsung Bioepis entered into ...